FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.

Item

http://www.wikidata.org/entity/Q35775254

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

FOLFIRI plus bevacizumab as se ...... domized phase III EAGLE study.

@ast

FOLFIRI plus bevacizumab as se ...... domized phase III EAGLE study.

@en

type

Item

label

FOLFIRI plus bevacizumab as se ...... domized phase III EAGLE study.

@ast

FOLFIRI plus bevacizumab as se ...... domized phase III EAGLE study.

@en

prefLabel

FOLFIRI plus bevacizumab as se ...... domized phase III EAGLE study.

@ast

FOLFIRI plus bevacizumab as se ...... domized phase III EAGLE study.

@en

P1476

FOLFIRI plus bevacizumab as se ...... ndomized phase III EAGLE study

@en

P2093

H Baba

http://www.w3.org/2001/XMLSchema#string

H Mishima

http://www.w3.org/2001/XMLSchema#string

H Tamagawa

http://www.w3.org/2001/XMLSchema#string

J Sakamoto

http://www.w3.org/2001/XMLSchema#string

K Ina

http://www.w3.org/2001/XMLSchema#string

K Kunieda

http://www.w3.org/2001/XMLSchema#string

K Kurachi

http://www.w3.org/2001/XMLSchema#string

M Inukai

http://www.w3.org/2001/XMLSchema#string

M Nakamura

http://www.w3.org/2001/XMLSchema#string

M Ooshiro

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.

FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study)

SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.

A comparison of sample size methods for the logrank statistic.

P304

1427-1433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDV197

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Koji Oba

P577

2015-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275356348

http://www.w3.org/2001/XMLSchema#string

P698

25908603

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

bevacizumab

P932

4478977

http://www.w3.org/2001/XMLSchema#string